Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Navamedic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Navamedic şirketinin toplam hissedar öz sermayesi NOK244.1M ve toplam borcu NOK136.3M olup, bu da borç-öz sermaye oranını 55.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NOK547.4M ve NOK303.3M dir. Navamedic 'in FAVÖK'ü NOK51.2M faiz karşılama oranı 9.5 dur. Şirketin NOK28.3M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

55.8%

Borç/özkaynak oranı

NOK 136.29m

Borç

Faiz karşılama oranı	9.5x
Nakit	NOK 28.32m
Eşitlik	NOK 244.10m
Toplam yükümlülükler	NOK 303.29m
Toplam varlıklar	NOK 547.39m

Son finansal sağlık güncellemeleri

Recent updates

Is Navamedic (OB:NAVA) Using Too Much Debt?

Sep 19

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Feb 18

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Nov 09

Is Navamedic (OB:NAVA) A Risky Investment?

Nov 02

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Feb 22

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Sep 04

Is Navamedic (OB:NAVA) Using Too Much Debt?

Apr 12

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

Feb 18

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Dec 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NAVA 'nin kısa vadeli varlıkları ( NOK289.4M ) kısa vadeli yükümlülüklerini ( NOK200.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: NAVA şirketinin kısa vadeli varlıkları ( NOK289.4M ) uzun vadeli yükümlülüklerini ( NOK102.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NAVA 'nin net borç/öz sermaye oranı ( 44.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: NAVA şirketinin borç/öz sermaye oranı son 5 yılda 26.4% seviyesinden 55.8% seviyesine yükseldi.

Borç Kapsamı: NAVA 'nin borcu işletme nakit akışı ( 4.1% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: NAVA 'in borcuna ilişkin faiz ödemeleri EBIT ( 9.5 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Navamedic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Navamedic (OB:NAVA) Using Too Much Debt?

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Is Navamedic (OB:NAVA) A Risky Investment?

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Is Navamedic (OB:NAVA) Using Too Much Debt?

Recent updates

Chief Executive Officer exercised options to buy kr2.2m worth of stock.

Consensus EPS estimates fall by 12%

Director recently bought kr1.5m worth of stock

Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023)

Price target decreased by 7.1% to kr45.50

First quarter 2024 earnings released

An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Consensus EPS estimates increase by 10%

Is Navamedic (OB:NAVA) Using Too Much Debt?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 53%

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 16%, revenue upgraded

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

First quarter 2023 earnings released

Price target increased by 8.7% to kr50.00

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Full year 2022 earnings released

Consensus EPS estimates increase by 20%, revenue downgraded

Navamedic ASA Launches Modifast in Norway

Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023

Price target increased to kr48.00

No independent directors

Consensus EPS estimates increase by 19%

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Third quarter 2022 earnings released

Is Navamedic (OB:NAVA) A Risky Investment?

Consensus forecasts updated

Price target decreased to kr44.00

Navamedic ASA Launches Forlaxgo®

Consensus EPS estimates increase by 50%

Consensus EPS estimates increase by 30%

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million .

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB.

Price target increased to kr50.00

No independent directors

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Full year 2021 earnings: Revenues exceed analyst expectations

Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea

Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022

Third quarter 2021 earnings released

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020)

Navamedic ASA Announces the Launch of New Products in the Nordics

Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden

First quarter 2021 earnings released

Is Navamedic (OB:NAVA) Using Too Much Debt?

New 90-day high: kr29.00

Full year 2020 earnings released

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

New 90-day high: kr22.60

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Navamedic ASA to Report Q2, 2021 Results on Aug 13, 2021

New 90-day low: kr17.45

New 90-day low: kr18.20

Chief Executive Officer exercised options to buy kr2.3m worth of stock.

New 90-day low: kr18.50

Earnings released